Cirio advised Abliva in connection with new share issue with deviation from the shareholders’ preferential rights

Cirio has advised Abliva AB (publ), listed on Nasdaq Stockholm, in connection with new share issue with deviation from the shareholders’ preferential rights.

The Board of Directors’ of Abliva resolved on 30 March 2021 to issue a total of 106,666,666 shares to Swedish and international qualified investors through two tranches. Tranche 1 consisted of 32,601,360 shares being issued based on the authorization from the Annual General Meeting on 20 May 2020. Tranche 2 consisted of 74,065,306 shares being issued after approval by an Extraordinary General Meeting on 29 April 2021. A prospectus for the admission to trading of the new shares issued in Tranche 2 was made public on 30 April 2021. The company received a total gross payment of SEK 80.0 million through the share issues.

Abliva develops medicines for the treatment of primary mitochondrial diseases. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Cirio advised Abliva with a team headed by Annika Andersson (Capital Markets and Public M&A), together with Oscar Lunde, Jesper M. Johansson and Louise Åberg (Capital Markets and Public M&A).